[Non-invasive evaluation of liver fibrosis in hepatitis C].
In 2007, the << Haute Autorité de Santé >> recommended FibroScan, FibroTest or liver biopsy for the initial diagnosis of fibrosis in patients with hepatitis C without co morbidities. These methods have to be interpreted according to the clinical situation, keeping in mind negative and positive false results. For FibroTest, hemolysis, Gilbert syndrome or acute inflammation can modify the result. Pre-analytical and analytical conditions of FibroTest have to be respected according to manufactory recommendations. For FibroScan, the numbers of measurements, the rate of successful measurements, and the interquartile range have to be correct. In case of suspicious results, FibroTest or FibroScan have to be done again. The liver biopsy, FibroTest, and FibroScan are less relevant for the distinction of two adjacent stages of fibrosis. However, their performances are excellent for the diagnosis of severe fibrosis or cirrhosis compared to moderate fibrosis.
de Lédinghen
V
V
Centre d'investigation de la Fibrose hépatique, CHU Bordeaux, Hôpital du Haut-Lévêque, 1, avenue de Magellan, 33604 Pessac, France. victor.deledinghen@chu-bordeaux.fr
Poynard
T
T
Wartelle
C
C
Rosenthal
E
E
D015415:Biomarkers / Q000032:analysis; D001706:Biopsy; D054459:Elasticity Imaging Techniques; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008111:Liver Function Tests / Q000379:methods
D015415:Biomarkers